COMMUNIQUÉS West-GlobeNewswire

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update
09/05/2024
Company to Host Conference Call Today, May 9, at 4:30pm ET BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing [...]
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
09/05/2024
– First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia (“AML”), on track for the second quarter of 2024 – SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- [...]
Sensus Healthcare Reports First Quarter 2024 Financial Results With Revenues up More than Three-fold
09/05/2024
Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; A djusted EBITDA (a non-GAAP measure) of $3.0 million, compared with negative $2.7 million in the prior-year quarter Launched the “Fair [...]
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
09/05/2024
Recent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025 Discussions to secure a partner to advance MAT2203 into the Phase 3 ORALTO trial remain on track [...]
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
09/05/2024
Late-Breaking Presentations of Initial Results From Phase 2 Studies of Atumelnant ( CRN 0 4894 ) in Congenital Adrenal Hyperplasia and ACTH-Dependent Cushing’s Syndrome Will be Presented at ENDO June 1-4, 2024 Following [...]
Telesis Bio Reports First Quarter 2024 Financial Results
09/05/2024
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid [...]
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
09/05/2024
Seminal Phase 2b ASCEND trial top-line data expected in fourth quarter of 2024 Projected available cash to fund planned operations into early 2026 covering all studies through data Conference call scheduled for today at [...]
Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule
09/05/2024
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the [...]
TELA Bio Reports First Quarter 2024 Financial Results
09/05/2024
MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial [...]
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
09/05/2024
REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
09/05/2024
-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable [...]
Sharecare announces first quarter 2024 financial results and operational highlights
09/05/2024
ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced financial results for the quarter ended March 31, [...]
Jushi Holdings Inc. Reports First Quarter 2024 Financial Results
09/05/2024
Expanded Gross Profit Margin to 49.4% Following Strong Execution of Operational Improvement Plan Net Loss of $18.4 Million , Compared to $12.4 Million in Q1 2023 Grew Adjusted EBITDA and Adjusted EBITDA Margin to $13.3 [...]
Morphic to Participate in RBC Capital Markets Global Healthcare Conference
09/05/2024
WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today [...]
Kronos Bio Reports First-Quarter 2024 Financial Results
09/05/2024
— $152.0 million cash runway into the second half of 2026 — — A study update on KB-0742-1001 will be presented at the upcoming American Society of Clinical Oncology (ASCO); expansion cohorts at new dose schedule remain [...]
Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results
09/05/2024
CANTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for [...]
HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
09/05/2024
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE [...]
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
09/05/2024
1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y 1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y-o-Y 1Q 2024 Adjusted EBITDA ( 1 ) of $26.4 Million, a 970% Increase Y-o-Y FY 2024 and [...]
R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new President and CEO
09/05/2024
MOUNTAIN VIEW, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial [...]

Pages